Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Neuroptika Logo
Neuroptika Growth Score
82
CB Rank
465846
Heat Score
69
Neuroptika’s mission is to improve patients’ lives by developing novel regenerative therapies for ophthalmic diseases
Founded
obfuscation
PrivateVenture - Series Unknown Cambridge, Massachusetts, United States1-10 www.neuroptika.com
Biotechnology
Health Care
Overview

Neuroptika
Growth Score
82
Heat Score
69

Growth Score82
-5 pts
in past quarter
Heat Score 69
-4 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Neuroptika

CB Rank
465846
Neuroptika’s mission is to improve patients’ lives by developing novel regenerative therapies for ophthalmic diseases
Founded
obfuscation
PrivateVenture - Series Unknown Cambridge, Massachusetts, United States1-10 www.neuroptika.com
Biotechnology
Health Care

Funding Rounds

Venture - Series Unknown
OBF
in
obfuscation

Details

Operating Status Active
Company Type For Profit
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

NRO-1
A therapeutic agent designed to protect and regenerate corneal nerves, aimed at treating dry eye disease and related ophthalmic conditions.
NRO-CMK
A gene therapy approach delivering CaMKII via intravitreal injection to protect retinal ganglion cells in neurodegenerative glaucoma.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Venture Round - Neuroptika Logo
Venture Round - Neuroptika
1
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Neuroptika Logo
Venture Round - Neuroptika
1
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Neuroptika Logo
Venture Round - Neuroptika
1
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Neuroptika Logo
Venture Round - Neuroptika
1
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Neuroptika Logo
Venture Round - Neuroptika
1
obfuscation
— Venture - Series Unknown

Funding Rounds

Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Venture Round - Neuroptika Logo
Venture Round - Neuroptika
1
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Neuroptika Logo
Venture Round - Neuroptika
1
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Neuroptika Logo
Venture Round - Neuroptika
1
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Neuroptika Logo
Venture Round - Neuroptika
1
obfuscation
— Venture - Series Unknown
obfuscation
Venture Round - Neuroptika Logo
Venture Round - Neuroptika
1
obfuscation
— Venture - Series Unknown

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Company K Partners Logo
Company K Partners
—
Venture Round - Neuroptika Logo
Venture Round - Neuroptika
—
Company K Partners Logo
Company K Partners
—
Venture Round - Neuroptika Logo
Venture Round - Neuroptika
—
Company K Partners Logo
Company K Partners
—
Venture Round - Neuroptika Logo
Venture Round - Neuroptika
—
Company K Partners Logo
Company K Partners
—
Venture Round - Neuroptika Logo
Venture Round - Neuroptika
—
Company K Partners Logo
Company K Partners
—
Venture Round - Neuroptika Logo
Venture Round - Neuroptika
—
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Contacts 1
News
Technology
View Tech Report

IT Spend

$79.8KThis year, Neuroptika is projected to spend $79.8K on IT, according to Aberdeen.

Active Website Tech Count

14Neuroptika is actively using 14 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, SSL by Default, and  Viewport Meta.

Total IP

1Neuroptika has 1 registered trademark in the 'Scientific and technological services' class, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Neuroptika's headquarters? Neuroptika is located in Cambridge, Massachusetts, United States.Who invested in Neuroptika? Neuroptika is funded by Company K Partners.When was the last funding round for Neuroptika? Neuroptika closed its last funding round on
obfuscation
from a Venture - Series Unknown round.Who are Neuroptika's competitors? Alternatives and possible competitors to Neuroptika may include Oculis, Sydnexis, and  REGENXBIO.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(9475511 1)
|